# 2invest

> 2invest is a VC fund in Heidelberg backing Biotechnology, Biopharma and Simulation. See 4 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Heidelberg, Germany
- Total investments: 4
- Last investment: Feb 2025
- Lead investor: 50%
- Last updated: Aug 2026
- Website: https://2invest-ag.com

2invest is a VC fund in Heidelberg focused on Biotechnology and Biopharma. 2invest AG is a listed company that acquires, holds, manages, and sells investments in corporations and partnerships, in particular, but not exclusively in the biotechnology, life science, and IT sectors in Germany and abroad.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 3 | 75% |
| Biopharma | 1 | 25% |
| Simulation | 1 | 25% |
| Life Science | 1 | 25% |
| Therapeutics | 1 | 25% |

6 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 2 | 50% |
| Series A | 1 | 25% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United Kingdom | 2 | 50% |
| Italy | 1 | 25% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Leucid Bio | Leucid Bio is a pioneering biotech company developing cell therapies for refractory cancers, especially solid tumors. Leucid was founded to translate 20 years of King's College London (King's) research in the CAR-T field and is led by a highly experienced management team with both scientific and commercial expertise. As part ofLeucid's ongoing relationship with King's, it benefits from exclusive access to and resources from the deep scientific, clinical, and manufacturing expertise of Dr. Maher and his academic team of immuno-oncology experts. | $8.9M | Series A | Feb 01, 2025 |  |
| NeoPhore | NeoPhore is a provider of novel small molecule therapies intended to treat cancer through stimulation of the immune system.The company's small molecule therapies target genetic mechanisms in order to create neoantigen which is known to stimulate the immune system and potentially be a weak spot in a tumor cell's defense mechanisms,enabling cancer patients to get treated and achieve improved clinical outcomes. | $12.2M | Series B | Feb 01, 2024 |  |
| NeoPhore | NeoPhore is a provider of novel small molecule therapies intended to treat cancer through stimulation of the immune system.The company's small molecule therapies target genetic mechanisms in order to create neoantigen which is known to stimulate the immune system and potentially be a weak spot in a tumor cell's defense mechanisms,enabling cancer patients to get treated and achieve improved clinical outcomes. | $7.4M | Series B | Jan 19, 2023 |  |
| Kither Biotech | Kither Biotech is a pharmaceutical product company that focuses its R&D activities on the development of new drugs. The R&D activities of the company mainly involve the development of new drugs to treat chronic inflammatory diseases.In recent years Kither has focused its first line of activities on the development of a small peptide(KIT2014) developed internally for the treatment of cystic fibrosis, a disease that predominantly affects the lungs and that currently has no cure. The KIT2014 peptide was assigned the Orphan Drug designation from the European Medicines Agency. The KIT2014 compound is currently undergoing the pre-clinical phase of clinical development.Kither’s product portfolio also includes a molecule (CL27), also developed internally, that is being developed for the treatment of Chronic Obstructive Pulmonary Diseases and Allergic Asthma. The company is about to start the pre-clinical phase of development of the CL27 molecule. | $20.4M | Series B | Mar 16, 2022 |  |

4 of 4 investments shown.

## Co-investors
- [Claris Ventures](https://shizune.co/investors/profile/claris-ventures) — VC Fund, 3 deals together
- [3B Future Health Fund](https://shizune.co/investors/profile/helsinn-investment-fund) — VC Fund, 3 deals together
- [Astellas Venture Management](https://shizune.co/investors/profile/astellas-venture-management) — VC Fund, 2 deals together
- Sixth Element Capital — VC Fund, 2 deals together
- [Ace Ventures](https://shizune.co/investors/profile/ace-ventures) — VC Fund, 1 deal together
- Alef 6 — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does 2invest invest in?

2invest invests primarily in Biotechnology, Biopharma and Simulation startups, most often at Series B and Series A stage. Most of the 4 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did 2invest last invest?

The most recent investment recorded for 2invest closed in Feb 2025. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co